ストックスクリーナーアプリを入手
69.73
0.75%
0.52
前日終値:
$69.21
開ける：
$68.88
24時間の取引高:
3.72M
Relative Volume:
1.71
時価総額：
$12.70B
収益：
$381.03M
当期純損益:
$-1.01B
株価収益率:
-11.72
EPS:
-5.95
ネットキャッシュフロー:
$-789.25M
1週間 パフォーマンス:
+3.26%
1か月 パフォーマンス:
-2.34%
6か月 パフォーマンス:
-7.22%
1年 パフォーマンス:
+22.38%
1日の値動き範囲:
$67.81
$71.19
1週間の範囲:
$65.56
$71.19
52週間の値動き範囲:
$53.69
$84.91
Insmed Inc Stock (INSM) Company Profile
INSM を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
INSM
Insmed Inc
|
69.73 | 12.30B | 381.03M | -1.01B | -789.25M | -5.95 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Insmed Inc Stock (INSM) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-05-13 | 開始されました | Jefferies | Buy |
| 2025-02-25 | 開始されました | RBC Capital Mkts | Outperform |
| 2024-04-23 | 開始されました | Truist | Buy |
| 2024-02-15 | 開始されました | Wolfe Research | Outperform |
| 2023-12-08 | 開始されました | Wells Fargo | Overweight |
| 2023-11-20 | 再開されました | JP Morgan | Overweight |
| 2023-07-26 | 開始されました | Guggenheim | Buy |
| 2022-12-09 | 開始されました | Mizuho | Buy |
| 2022-12-07 | 開始されました | Barclays | Overweight |
| 2022-11-18 | 開始されました | BofA Securities | Buy |
| 2022-04-27 | 開始されました | Goldman | Buy |
| 2021-12-06 | 開始されました | JP Morgan | Overweight |
| 2021-10-19 | 再開されました | Monness Crespi & Hardt | Buy |
| 2021-10-19 | 再開されました | Morgan Stanley | Overweight |
| 2021-10-08 | 開始されました | Cantor Fitzgerald | Overweight |
| 2021-04-26 | 再開されました | Credit Suisse | Outperform |
| 2020-12-17 | 開始されました | Berenberg | Buy |
| 2020-10-12 | 再開されました | Stifel | Buy |
| 2019-09-03 | 開始されました | Goldman | Buy |
| 2019-04-09 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-02-15 | アップグレード | JMP Securities | Mkt Perform → Mkt Outperform |
| 2019-01-17 | アップグレード | Goldman | Neutral → Buy |
| 2019-01-02 | 開始されました | Canaccord Genuity | Buy |
| 2018-08-06 | ダウングレード | JMP Securities | Mkt Outperform → Mkt Perform |
| 2018-07-23 | 開始されました | Goldman | Neutral |
| 2018-04-23 | アップグレード | Credit Suisse | Neutral → Outperform |
| 2018-03-21 | 開始されました | Morgan Stanley | Overweight |
| 2018-01-18 | 開始されました | Credit Suisse | Neutral |
| 2017-09-05 | 繰り返されました | Evercore ISI | Outperform |
| 2017-08-17 | 開始されました | Evercore ISI | Outperform |
| 2017-07-11 | 開始されました | Robert W. Baird | Outperform |
| 2016-03-15 | 開始されました | Stifel | Buy |
| 2015-11-09 | ダウングレード | UBS | Buy → Neutral |
| 2015-10-06 | 繰り返されました | H.C. Wainwright | Buy |
| 2015-06-09 | 開始されました | Citigroup | Neutral |
| 2014-03-26 | 繰り返されました | HC Wainwright | Buy |
すべてを表示
Insmed Inc (INSM) 最新ニュース
If You Invested $100 In This Stock 5 Years Ago, You Would Have This Much Today - Benzinga
Insmed To Present at the 2025 Goldman Sachs Annual Global Health - GuruFocus
Insmed To Present at the 2025 Goldman Sachs Annual Global Healthcare Conference - marketscreener.com
Insmed’s SWOT analysis: rare disease biotech stock shows promise amid challenges - Investing.com
8MM Bronchiectasis Market Opportunity Assessment and Forecasts, 2033 - GlobeNewswire Inc.
Insmed Says Brensocatib Showed Consistent Efficacy in Non-Cystic Fibrosis Bronchiectasis - marketscreener.com
Insmed (INSM) Highlights Promising Brensocatib Trial Results at - GuruFocus
Insmed (INSM) Highlights Promising Brensocatib Trial Results at ATS 2025 | INSM Stock News - GuruFocus
Brensocatib Shows Consistent Efficacy and Safety Across Three Prespecified Subgroups in New Data from Landmark ASPEN Study - Yahoo Finance
Captrust Financial Advisors Sells 631 Shares of Insmed Incorporated (NASDAQ:INSM) - Defense World
Mercer Global Advisors Inc. ADV Acquires New Position in Insmed Incorporated (NASDAQ:INSM) - Defense World
HC Wainwright Issues Optimistic Outlook for Insmed Earnings - Defense World
INSMED Executives Sell Shares to Satisfy Tax Obligations - TradingView
Jefferies Financial Group Initiates Coverage on Insmed (NASDAQ:INSM) - Defense World
Jefferies Initiates Coverage of Insmed (BIT:1INSM) with Buy Recommendation - Nasdaq
Insmed Incorporated (INSM): Among Small-Cap Healthcare Stocks Hedge Funds Are Buying - Insider Monkey
Jefferies Initiates Coverage of Insmed (BMV:INSM) with Buy Recommendation - Nasdaq
Jefferies sets $105 target on Insmed stock with Buy rating By Investing.com - Investing.com Nigeria
Insmed at Bank of America 2025 Healthcare Conference: Strategic Pipeline Focus - Investing.com
Jefferies Initiates Coverage on INSM with a Buy Rating and $105 PT | INSM Stock News - GuruFocus
Jefferies Initiates Coverage of Insmed (LSE:0JAV) with Buy Recommendation - Nasdaq
Unlocking Insmed (INSM) International Revenues: Trends, Surprises, and Prospects - Yahoo Finance
This Insmed Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Benzinga
Jefferies Initiates Coverage of Insmed (INSM) with Buy Recommendation - Nasdaq
Jefferies Initiates Coverage on Insmed With Buy Rating, $105 Price Target - marketscreener.com
Jefferies sets $105 target on Insmed stock with Buy rating - Investing.com
Insmed (NASDAQ:INSM) Given Buy Rating at HC Wainwright - Defense World
Insmed (INSM) Gains Buy Rating from Jefferies with Promising Out - GuruFocus
Insmed (INSM) Receives Reaffirmed Buy Rating from HC Wainwright - GuruFocus
Analyst Expectations For Insmed's Future - Benzinga
Insmed Incorporated (NASDAQ:INSM) Given Consensus Rating of “Buy” by Analysts - Defense World
UBS Group Cuts Insmed (NASDAQ:INSM) Price Target to $109.00 - Defense World
Insmed (INSM) Reports Q1 Loss, Tops Revenue Estimates - MSN
Analysts Are Updating Their Insmed Incorporated (NASDAQ:INSM) Estimates After Its First-Quarter Results - Yahoo Finance
Insmed Incorporated (NASDAQ:INSM) Q1 2025 Earnings Call Transcript - Insider Monkey
Insmed (INSM) Receives Slight Price Target Adjustment by UBS | I - GuruFocus
UBS Maintains Buy Rating, Lowers Price Target for Insmed (INSM) - GuruFocus
Insmed's Q1 Loss Wider Than Expected, Sales Match Estimates - TradingView
$1000 Invested In This Stock 5 Years Ago Would Be Worth This Much Today - Benzinga
Is Insmed Incorporated (INSM) the Best Cancer Stock to Invest in for Long-Term Gain? - Insider Monkey
Insmed (INSM) Receives Slight Price Target Adjustment by UBS | INSM Stock News - GuruFocus
RBC Trims Price Target on Insmed to $99 From $100, Keeps Outperform Rating - marketscreener.com
Insmed: Q1 Earnings Snapshot - Greenwich Time
Decoding Insmed Inc (INSM): A Strategic SWOT Insight - GuruFocus
Insmed’s Earnings Call: Strong Growth and Optimistic Outlook - TipRanks
Insmed Q1 2025 Earnings Call Transcript - MarketBeat
Transcript : Insmed Incorporated, Q1 2025 Earnings Call, May 08, 2025 - marketscreener.com
Earnings call transcript: Insmed Q1 2025 shows mixed results with slight EPS miss - Investing.com
Insmed Q1 Net Loss Widens, Revenue Increases; 2025 Revenue Guidance Maintained - marketscreener.com
Insmed (INSM) Reports Q1 Revenue Surpassing Expectations and Awaits Key Approvals | INSM Stock News - GuruFocus
Insmed Q1 2025 slides: ARIKAYCE sales surge 23% as brensocatib launch approaches - Investing.com
Insmed Inc (INSM) 財務データ
収益
当期純利益
現金流量
EPS
1.89%
3.74%
大文字化:
|
ボリューム (24 時間):